Everything below concerns purity. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-06. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
=== Drug metabolism === The drug hydroxyzine is broken down into its main metabolite cetirizine by alcohol dehydrogenase. Other drugs with alcohol groups may be metabolized in a similar way as long as steric hindrance does not prevent the alcohol from reaching the active site. A study reported that a gut microbial AdhE can also metabolize metformin. AdhE from Eubacterium hallii was shown to directly bind and enzymatically inactivate metformin, reducing intestinal and systemic drug exposure and contributing to reduced therapeutic response in type 2 diabetes.
Glycolipid transfer proteins Lipocalins including retinol binding proteins and fatty acid-binding proteins Polyisoprenoid-binding protein, such as YceI protein domain Ganglioside GM2 activator proteins CRAL-TRIO domain (α-Tocopherol and phosphatidylinositol sec14p transfer proteins) Sterol carrier proteins Phosphatidylinositol transfer proteins and STAR domains Oxysterol-binding protein
A liquid in an area of low pressure (vacuum) vaporizes and forms bubbles, which then collapse as they enter high pressure areas. This causes liquid to fill the cavities left by the bubbles with tremendous localized force, eroding any adjacent solid surface.
In testimony before the US Senate Foreign Relations Committee on 28 January, US Secretary of State Marco Rubio did not confirm the story when asked by Senator Jeanne Shaheen and instead only noted that Rodríguez had not been indicted, saying: "We are dealing with individuals that in our system would not be acceptable in the long term. But we are in a transition to stabilization phase. You have to work with the people currently in charge of the elements of government."
To study the effect of various preparation of Testosterone on Steroid Profiling and Delta Value of 13C/12C of Testosterone Metabolite in volunteers with Normal/Abnormal Testosterone/ Epitestosterone (T/E) Ratio. Indian Herbal Drugs : Identification of stimulants, narcotics and other substances with potential of ergogenic aids in sports. Characterization of physiochemical properties and analysis of liposomes in human biological samples using hyphenated analytical technique. Detection of Stanozolol conjugated metabolites by liquid chromatography tandem-mass spectrometry. Prednisone excretion study and identification of its marker metabolites. Rapid determination of urinary phthalates using liquid chromatography tandem mass spectrometry. Identification of various banned small peptides in human urine using liquid chromatography tandem mass spectrometry.
Sources: en.wikipedia.org
The above explanation is merely a simple introduction to vacuum pumping, and is not representative of the entire range of pumps in use. Many variations of the positive displacement pump have been developed, and many other pump designs rely on fundamentally different principles. Momentum transfer pumps, which bear some similarities to dynamic pumps used at higher pressures, can achieve much higher quality vacuums than positive displacement pumps. Entrapment pumps can capture gases in a solid or absorbed state, often with no moving parts, no seals and no vibration. None of these pumps are universal; each type has important performance limitations. They all share a difficulty in pumping low molecular weight gases, especially hydrogen, helium, and neon. The lowest pressure that can be attained in a system is also dependent on many things other than the nature of the pumps. Multiple pumps may be connected in series, called stages, to achieve higher vacuums. The choice of seals, chamber geometry, materials, and pump-down procedures will all have an impact. Collectively, these are called vacuum technique. And sometimes, the final pressure is not the only relevant characteristic. Pumping systems differ in oil contamination, vibration, preferential pumping of certain gases, pump-down speeds, intermittent duty cycle, reliability, or tolerance to high leakage rates. In ultra high vacuum systems, some very "odd" leakage paths and outgassing sources must be considered.
23 August – It is reported that doctors at Oxford's Churchill Hospital have carried out the UK's first womb transplant, with a 34-year-old woman receiving her sister's womb in a 17-hour operation that took place in February 2023. 24 August Data released by the Home Office shows that 175,000 people were waiting to have their claims for asylum assessed at the end of June 2023, an increase of 44% on the same time in 2022. GCSE results are published in England, Wales and Northern Ireland, with 68.2% of all entries marked at grades 4/C and above. It is the second fall in overall results, taking them almost back to pre-pandemic levels. 25 August Ofgem confirms the energy price cap will fall again in October, with an annual gas and electricity bill at around £1,923. The National Crime Agency launches a criminal investigation after linking 88 UK deaths with an online seller from Canada accused of selling them a poisonous substance so they could commit suicide. 26 August – Conservative MP Nadine Dorries resigns her Parliamentary seat two months after originally saying she would do so, accusing Prime Minister Rishi Sunak of abandoning "the fundamental principles of Conservatism" and that "history will not judge [him] kindly". 28 August – Hundreds of flights to and from the UK are delayed following technical problems with the UK's air traffic control system.
== Function == INSIG1 plays an important role in the SREBP-mediated regulation of cholesterol biosynthesis: by binding to the sterol-sensing domain of SCAP (SREBP cleavage activating protein) it makes the SCAP/SREBP complex stay longer in the ER, thus prohibiting SCAP from carrying activated SREBP to the golgi complex. This ultimately blocks SREBP from acting as a transcription factor for the SRE in the promoter region of the HMG-CoA-reductase gene and results in a decreased expression of HMG-CoA-reductase. INSIG1 also binds to the sterol-sensing domain of HMG-CoA-reductase, resulting in the enzyme's increased degradation. Both functions require the binding of INSIG1 protein via the same site. There are two other proteins whose sterol-binding sites show a great similarity to the ones of SCAP and HMG-CoA-reductase and who might thus be regulated by INSIG1 as well:
=== Family record book (1877) === The loss of Parisian civil records largely influenced the creation of the family record book in 1877, introduced by a circular from Jules Simon, President of the Council and Minister of the Interior. The circular explicitly referenced the Commune’s destruction, stating that “family record books will serve as a third deposit of civil records entrusted to individuals and will provide valuable information should registers be destroyed.” The law of April 5, 1884, concerning municipal organization, required town halls to budget for the costs of family record books.
=== Lock and key hypothesis === This concept was suggested by the 19th-century chemist Emil Fischer. He proposed that the active site and substrate are two stable structures that fit perfectly without any further modification, just like a key fits into a lock. If one substrate perfectly binds to its active site, the interactions between them will be strongest, resulting in high catalytic efficiency. As time went by, limitations of this model started to appear. For example, the competitive enzyme inhibitor methylglucoside can bind tightly to the active site of 4-alpha-glucanotransferase and perfectly fits into it. However, 4-alpha-glucanotransferase is not active on methylglucoside and no glycosyl transfer occurs. The Lock and Key hypothesis cannot explain this, as it would predict a high efficiency of methylglucoside glycosyl transfer due to its tight binding. Apart from competitive inhibition, this theory cannot explain the mechanism of action of non-competitive inhibitors either, as they do not bind to the active site but nevertheless influence catalytic activity.
Sources: en.wikipedia.org
=== Secondary neoplasm === Development of secondary neoplasia after successful chemotherapy or radiotherapy treatment can occur. The most common secondary neoplasm is secondary acute myeloid leukemia, which develops primarily after treatment with alkylating agents or topoisomerase inhibitors. Survivors of childhood cancer are more than 13 times as likely to get a secondary neoplasm during the 30 years after treatment than the general population. Not all of this increase can be attributed to chemotherapy.
== Mechanisms == VIP binds to both VPAC1 and VPAC2 receptors. When VIP binds to VPAC2 receptors, a G-alpha-mediated signaling cascade is triggered. In a number of systems, VIP binding activates adenyl cyclase activity leading to increases in cAMP concentration and PKA activity. The PKA then activates other intracellular signaling pathways like the phosphorylation of CREB and other transcriptional factors. The mPer1 and mPer2 promoters have CRE domains and thus provides the mechanism for VIP to regulate the molecular clock itself. Then it will activate gene expression pathways such as Per1 and Per2 in circadian rhythm. In addition, GABA levels are connected to VIP in that they are co-released. Sparse GABAergic connections are thought to decrease synchronized firing. While GABA controls the amplitude of SCN neuronal rhythms, it is not critical for maintaining synchrony. However, if GABA release is dynamic, it may mask or amplify synchronizing effects of VIP inappropriately. Circadian time is likely to affect the synapses rather than the organization of VIP circuits.
compared perianal injectable bulking agents to sphincter training and biofeedback, and found the former to be superior. Both methods lead to an improvement of FI, but comparisons of St Mark's scores between the groups showed no difference between treatments. Anal manometry is sometimes used to investigate changes in the anal canal before and after the procedure. Usually mean anal resting pressure and mean anal squeeze pressure are the parameters used. Improvements in these measurements are often, but not always reported up to 3–12 months after the procedure. These improvements are not always maintained after 12 months. The length of the anal canal has also been reported to increase following the procedure. In one report, dextranomer did not increase anal resting or squeeze pressures. In the same study, dextranomer injections were found to be no different to biofeedback. There is limited research available on this topic, and these publications are mostly of poor quality. Apart from the available research, most of the claims of benefit of these procedures is anecdotal. One author criticized these procedures, stating that simply narrowing the anal canal was an instinctive and naïve solution which does not consider the complex pathopysiological mechanisms of FI. They suggested that these treatments are in theory suitable only for passive and minor forms of FI. Concerns have been raised about migration of the particles (in the case of Durasphere) away from the site of injection, or the total resorption of the material (in the case of hyaluronic acid and hydroxyl coaptite).
NOW!!" The journalists who covered the investigation argued that Purdue Pharma has insisted on a 12-hour duration of action for nearly all patients, despite evidence to the contrary, to protect the reputation of OxyContin as a 12-hour drug and the willingness of health insurance and managed care companies to cover OxyContin despite its high cost relative to generic opiates such as morphine. Purdue sales representatives were instructed to encourage doctors to write prescriptions for larger 12-hour doses instead of more frequent dosing. An August 1996 memo to Purdue sales representatives in Tennessee entitled "$$$$$$$$$$$$$ It's Bonus Time in the Neighborhood!" reminded the representatives that their commissions would dramatically increase if they were successful in convincing doctors to prescribe larger doses. Los Angeles Times journalists argue using interviews from opioid addiction experts that such high doses of OxyContin spaced 12 hours apart create a combination of agony during opiate withdrawal (lower lows) and a schedule of reinforcement that relieves this agony fostering addiction. As of 2026, the prescribing information for OxyContin still specifies a controversial 12-hour dosing schedule - which experts say promotes addiction - as the only option; it also still states, "there are no well-controlled clinical studies evaluating the safety and efficacy with dosing more frequently than every 12 hours."
=== Mechanism of action === Bulevirtide binds and inactivates the sodium/bile acid cotransporter, blocking both hepatitis B and hepatitis D viruses from entering hepatocytes. The hepatitis B virus uses its surface lipopeptide pre-S1 for docking to mature liver cells via their sodium/bile acid cotransporter (NTCP) and subsequently entering the cells. Myrcludex B is a synthetic N-acylated pre-S1 that can also dock to NTCP, blocking the virus's entry mechanism. Bulevirtide is also effective against hepatitis D because the hepatitis D virus uses the same entry receptor as the hepatitis B virus and is only effective in the presence of a hepatitis B virus infection. Pre-clinical data in mice suggests that pharmacological inhibition of NTCP-mediated bile salt uptake may also be effective to lower hepatic bile salt accumulation in cholestatic conditions. This reduces hepatocellular damage. An increased ratio of phospholipid to bile salts seen in bile upon NTCP inhibition may further contribute to the protective effect as bile salts are less toxic in presence of phospholipids.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.